Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

An Extracellular Vesicle-Based Platform for Chimeric Antigen Receptor (CAR) Cancer Immunotherapy

EF 2023-24

Résumé
With 2 in 5 Canadians facing a cancer diagnosis, urgent advancements in cancer therapies are imperative. One emerging field in cancer therapeutics research is chimeric antigen receptor (CAR) therapy, which involves engineering a cancer-targeting receptor onto the patient's immune cells. This innovative approach provides the patient's immune system with critical information, enhancing its ability to detect and kill cancer cells in the body. Although promising, current CAR therapies are personalized to each patient, rendering them expensive and challenging for widespread clinical application. In addressing these limitations, our lab's focus turns to extracellular vesicles. All cell types in the body (including our immune cells) produce extracellular vesicles, essentially tiny bubbles released by cells. These vesicles carry substances like proteins and genetic material, playing a critical role in cell communication. Extracellular vesicles produced by CAR-engineered cells contain all the therapeutic components, including the cancer-targeting receptor, required for killing cancer cells. Therefore, as an alternative to personalized CAR therapies, our lab's research aims to produce and optimize extracellular vesicles derived from CAR-engineered immune cells as a potential off-the-shelf delivery method for cancer immunotherapy. The primary advantage of this therapy capitalizes on the heightened production of extracellular vesicles when immune cells get stimulated. Therefore, this would allow for high-scale production, increasing treatment accessibility to cancer patients. In essence, the overarching goal of this research is to optimize and extend cancer immunotherapies to patients who would not previously have access to them, thereby improving overall cancer survival outcomes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
507047
Name
Synek Tamara M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
An Extracellular Vesicle-Based Platform for Chimeric Antigen Receptor (CAR) Cancer Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Car Nk Cell Therapy; Car T Cell Therapy; Exosomes; Extracellular Vesicles; Fast Protein; Lentiviral Vector
Abstract
With 2 in 5 Canadians facing a cancer diagnosis, urgent advancements in cancer therapies are imperative. One emerging field in cancer therapeutics research is chimeric antigen receptor (CAR) therapy, which involves engineering a cancer-targeting receptor onto the patient's immune cells. This innovative approach provides the patient's immune system with critical information, enhancing its ability to detect and kill cancer cells in the body. Although promising, current CAR therapies are personalized to each patient, rendering them expensive and challenging for widespread clinical application. In addressing these limitations, our lab's focus turns to extracellular vesicles. All cell types in the body (including our immune cells) produce extracellular vesicles, essentially tiny bubbles released by cells. These vesicles carry substances like proteins and genetic material, playing a critical role in cell communication. Extracellular vesicles produced by CAR-engineered cells contain all the therapeutic components, including the cancer-targeting receptor, required for killing cancer cells. Therefore, as an alternative to personalized CAR therapies, our lab's research aims to produce and optimize extracellular vesicles derived from CAR-engineered immune cells as a potential off-the-shelf delivery method for cancer immunotherapy. The primary advantage of this therapy capitalizes on the heightened production of extracellular vesicles when immune cells get stimulated. Therefore, this would allow for high-scale production, increasing treatment accessibility to cancer patients. In essence, the overarching goal of this research is to optimize and extend cancer immunotherapies to patients who would not previously have access to them, thereby improving overall cancer survival outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Synek, Tamara M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~